LGR5在子宫内膜癌中的表达及其意义

发布时间：2018-04-25 07:19

  本文选题：富含亮氨酸重复序列G蛋白偶联受体 + 子宫内膜癌　； 参考：《实用妇产科杂志》2017年02期

【摘要】：目的:探讨富含亮氨酸重复序列G蛋白偶联受体5(LGR5)在子宫内膜癌中的表达情况及其与临床病理因素的关系。方法:采用免疫组织化学SABC法检测90例子宫内膜癌及30例正常子宫内膜组织中LGR5表达情况,并分析其与临床病理因素的关系。结果:LGR5在子宫内膜癌组织中的阳性表达率(63.3%)显著高于正常子宫内膜(23.3%)(P0.001)。LGR5在1/2肌层浸润组的阳性表达率(72.5%)显著高于≥1/2肌层浸润组(33.3%)(P=0.001)。LGR5的阳性表达率在年龄、病理类型、组织学分级、宫颈累及、淋巴结转移、FIGO分期组间差异均无统计学意义(P0.05)。多因素分析发现LGR5是子宫内膜癌有无肌层浸润的独立影响因素(OR=0.163,95%CI 0.034~0.772,P=0.022)。结论:LGR5在子宫内膜癌组织中表达上调,提示与肌层浸润深度相关,可能在子宫内膜癌的发生中起一定作用。
[Abstract]:Objective: to investigate the expression of Leucine-rich repeat G protein coupled receptor 5 LGR5 in endometrial carcinoma and its relationship with clinicopathological factors. Methods: immunohistochemical SABC method was used to detect the expression of LGR5 in 90 cases of endometrial carcinoma and 30 cases of normal endometrium, and the relationship between the expression of LGR5 and clinicopathological factors was analyzed. Results the positive expression rate of 10% LGR5 in endometrial carcinoma (63.3%) was significantly higher than that in normal endometrium (23.3%). The positive expression rate of LGR5 in 1 / 2 myometrium infiltrating group was significantly higher than that in 鈮，

本文编号：1800335